FDA Grants Traditional Approval to Daratumumab and Hyaluronidase-fihj for Newly Diagnosed Light Chain Amyloidosis

On November 19, the FDA granted traditional approval to daratumumab and hyaluronidase-fihj with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed light chain amyloidosis. For more information, read the FDA announcement and visit the Janssen Biotech website.

On November 19, the FDA granted traditional approval to daratumumab and hyaluronidase-fihj with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed light chain amyloidosis.

For more information, read the FDA announcement and visit the Janssen Biotech website.

Posted on 11/21/2025